@article{3d3255ec6797476aba76a33bb7923b10,
title = "Myelodysplastic syndromes, version 2.2015 featured updates to the NCCN guidelines",
abstract = "The NCCN Guidelines for Myelodysplastic Syndromes (MDS) comprise a heterogeneous group of myeloid disorders with a highly variable disease course that depends largely on risk factors. Risk evaluation is therefore a critical component of decision-making in the treatment of MDS. The development of newer treatments and the refinement of current treatment modalities are designed to improve patient outcomes and reduce side effects. These NCCN Guidelines Insights focus on the recent updates to the guidelines, which include the incorporation of a revised prognostic scoring system, addition of molecular abnormalities associated with MDS, and refinement of treatment options involving a discussion of cost of care.",
author = "Greenberg, {Peter L.} and Stone, {Richard M.} and Rafael Bejar and Bennett, {John M.} and Bloomfield, {Clara D.} and Uma Borate and {De Castro}, {Carlos M.} and Deeg, {H. Joachim} and DeZern, {Amy E.} and Fathi, {Amir T.} and Olga Frankfurt and Karin Gaensler and Guillermo Garcia-Manero and Griffiths, {Elizabeth A.} and David Head and Virginia Klimek and Rami Komrokji and Kujawski, {Lisa A.} and Maness, {Lori J.} and O'Donnell, {Margaret R.} and Pollyea, {Daniel A.} and Bart Scott and Shami, {Paul J.} and Stein, {Brady L.} and Peter Westervelt and Benton Wheeler and Shead, {Dorothy A.} and Courtney Smith",
note = "Publisher Copyright: {\textcopyright} JNCCN-Journal of the National Comprehensive Cancer Network. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.",
year = "2015",
month = mar,
day = "1",
doi = "10.6004/jnccn.2015.0038",
language = "English (US)",
volume = "13",
pages = "261--272",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "3",
}